1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Critical Clinical Trial Updates Expected in 3Q

 
• By Lucie Ellis-Taitt

Ten clinical trial data readouts to watch for in the third quarter of 2017 that are expected to shift stocks and potentially change standard of care options in some disease areas.

Coming soon
Scrip lists the clinical trial catalysts likely to impact markets in 3Q 2017 • Source: Shutterstock

The third quarter of 2017 will see several pharmaceutical companies report critical Phase III data for novel drugs in Alzheimer's disease, epilepsy, immunology conditions and rare and genetic diseases. Also, in the coming weeks, AstraZeneca PLC will announce data for its programmed death-ligand 1 (PD-L1) inhibitor Imfinzi in NSCLC – critical results that will make or break the drug in the first-line treatment setting where it is already trailing behind its peers.

Analysts from Biomedtracker, in a new Q3 2017 OutlookReport, have outlined data and US regulatory catalysts for more than 20 drugs that are expected to occur in the third quarter....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.